James P. Hughes

Appointments and Affiliations
 
 
Fred Hutchinson Cancer Research Center
Public Health Sciences
Member
University of Washington
School of Public Health and Community Medicine
Biostatistics
Professor
 Professional Headshot of James P. Hughes

Mailing Address

Department of Biostatistics 357232
University of Washington
Seattle, Washington 98195
United States

Degrees

Ph.D., University of Washington, Statistics, 1993.
M.S., University of Washington, Biomathematics, 1980.
B.S., University of Maine, Wildlife Ecology, 1977.

Research Interests

Statistical methods for for HIV/STI research;
community randomized trials;
hidden Markov models;

Memberships

American Statistical Association
International Biometric Society

 

Recent Publications

2013
Eshleman, SH, Hughes JP, Laeyendecker O, Wang J, Brookmeyer R, Johnson-Lewis L, Mullis CE, Hackett J, Vallari AS, Justman J et al..  2013.  Use of a multi-faceted approach to analyze HIV incidence in a cohort study of women in the United States: HIV Prevention Trials Network 064 Study.. The Journal of infectious diseases. 207(2):223-31. Abstract
Hodder, SL, Justman J, Hughes JP, Wang J, Haley DF, Adimora AA, del Rio C, Golin CE, Kuo I, Rompalo A et al..  2013.  HIV acquisition among women from selected areas of the United States: a cohort study.. Annals of internal medicine. 158(1):10-8. Abstract
Lingappa, J, Thomas KK, Hughes JP, Baeten JM, Wald A, Farquhar C, de Bruyn G, Fife KH, Campbell MS, Kapiga S et al..  2013.  Partner characteristics predicting HIV-1 setpoint in sexually acquired HIV-1 among African seroconverters.. AIDS research and human retroviruses. 29(1):164-71. Abstract
Dai, JY, Gilbert PB, Hughes JP, Brown ER.  2013.  Estimating the Efficacy of Preexposure Prophylaxis for HIV Prevention Among Participants With a Threshold Level of Drug Concentration.. American journal of epidemiology. 177(3):256-63. Abstract
Broad, JM, Manhart LE, Kerani RP, Scholes D, Hughes JP, Golden MR.  2013.  Chlamydia screening coverage estimates derived using healthcare effectiveness data and information system procedures and indirect estimation vary substantially.. Sexually transmitted diseases. 40(4):292-7. Abstract
Alsallaq, RA, Baeten JM, Celum CL, Hughes JP, Abu-Raddad LJ, Barnabas RV, Hallett TB.  2013.  Understanding the Potential Impact of a Combination HIV Prevention Intervention in a Hyper-Endemic Community.. PloS one. 8(1):e54575. Abstract
2012
Dai, JY, Hughes JP.  2012.  A unified procedure for meta-analytic evaluation of surrogate end points in randomized clinical trials.. Biostatistics (Oxford, England). 13(4):609-24. Abstract
Kahle, EM, Hughes JP, Lingappa JR, John-Stewart G, Celum C, Nakku-Joloba E, Njuguna S, Mugo N, Bukusi E, Manongi R et al..  2012.  An empiric risk scoring tool for identifying high-risk heterosexual HIV-1 serodiscordant couples for targeted HIV-1 prevention.. Journal of acquired immune deficiency syndromes (1999). Abstract
Winer, RL, Hughes JP, Feng Q, Xi L, Lee S-K, O'Reilly SF, Kiviat NB, Koutsky LA.  2012.  Prevalence and risk factors for oncogenic human papillomavirus infections in high-risk mid-adult women.. Sexually transmitted diseases. 39(11):848-56. Abstract
Edelstein, ZR, Schwartz SM, Hawes S, Hughes JP, Feng Q, Stern ME, O'Reilly S, Lee S-K, Xi L, Koutsky LA.  2012.  Rates and determinants of oral human papillomavirus infection in young men.. Sexually transmitted diseases. 39(11):860-7. Abstract
Lu, Y, Celum C, Wald A, Baeten JM, Cowan F, Delany-Moretlwe S, Reid SE, Hughes JP, Wilcox E, Corey L et al..  2012.  Acyclovir achieves lower concentration in African HIV-seronegative, HSV-2 seropositive women compared to non-African populations.. Antimicrobial agents and chemotherapy. 56(5):2777-9. Abstract
Baeten, JM, Reid SE, Delany-Moretlwe S, Hughes JP, Wang RS, Wilcox E, Limbada M, Akpomiemie G, Corey L, Wald A et al..  2012.  Clinical and virologic response to episodic acyclovir for genital ulcers among HIV-1 seronegative, herpes simplex virus type 2 seropositive African women: a randomized, placebo-controlled trial.. Sexually transmitted diseases. 39(1):21-4. Abstract
García, PJ, Holmes KK, Cárcamo CP, Garnett GP, Hughes JP, Campos PE, Whittington WLH.  2012.  Prevention of sexually transmitted infections in urban communities (Peru PREVEN): a multicomponent community-randomised controlled trial.. Lancet. Abstract
Hughes, JP, Baeten JM, Lingappa JR, Magaret AS, Wald A, de Bruyn G, Kiarie J, Inambao M, Kilembe W, Farquhar C et al..  2012.  Determinants of Per-Coital-Act HIV-1 Infectivity Among African HIV-1-Serodiscordant Couples.. The Journal of infectious diseases. 205(3):358-365. Abstract
Murnane, PM, Hughes JP, Celum C, Lingappa JR, Mugo N, Farquhar C, Kiarie J, Wald A, Baeten JM.  2012.  Using plasma viral load to guide antiretroviral therapy initiation to prevent HIV-1 transmission.. PloS one. 7(11):e51192. Abstract
2011
Xi, L, Hughes JP, Castle PE, Edelstein ZR, Wang C, Galloway DA, Koutsky LA, Kiviat NB, Schiffman M.  2011.  Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study.. The Journal of infectious diseases. 203(10):1425-33. Abstract
Jacob, ST, Baeten JM, Hughes JP, Peinado J, Wang J, Sanchez J, Reid SE, Delany-Moretlwe S, Cowan F, Fuchs JD et al..  2011.  A post-trial assessment of factors influencing study drug adherence in a randomized biomedical HIV-1 prevention trial.. AIDS and behavior. 15(5):897-904. Abstract
Eshleman, SH, Hudelson SE, Redd AD, Wang L, Debes R, Chen YQ, Martens CA, Ricklefs SM, Selig EJ, Porcella SF et al..  2011.  Analysis of Genetic Linkage of HIV From Couples Enrolled in the HIV Prevention Trials Network 052 Trial.. The Journal of infectious diseases. 204 (12):1918-1926. Abstract
Bernabe-Ortiz, A, Carcamo CP, Scott JD, Hughes JP, Garcia PJ, Holmes KK.  2011.  HBV infection in relation to consistent condom use: a population-based study in Peru.. PloS one. 6(9):e24721. Abstract
Campbell, MS, Mullins JI, Hughes JP, Celum C, Wong KG, Raugi DN, Sorensen S, Stoddard JN, Zhao H, Deng W et al..  2011.  Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial.. PloS one. 6(3):e16986. Abstract
2010
Kim, HN, Wang J, Hughes JP, Coombs R, Sanchez J, Reid S, Delany-Moretlwe S, Cowan F, Fuchs J, Eshleman SH et al..  2010.  Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.. The Journal of infectious diseases. 202(5):734-8. Abstract
Lingappa, JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E et al..  2010.  Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.. Lancet. 375(9717):824-33. Abstract
Celum, C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, Mujugira A, Baeten JM, Mullins JI, Hughes JP et al..  2010.  Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.. The New England journal of medicine. 362(5):427-39. Abstract
Donnell, D, Hughes JP, Fleming TR.  2010.  Challenges in the design of HIV prevention trials in the United States.. Journal of acquired immune deficiency syndromes (1999). 55 Suppl 2:S136-40. Abstract
Fuchs, J, Celum C, Wang J, Hughes JP, Sanchez J, Cowan F, Reid S, Delany-Moretlwe S, Corey L, Wald A.  2010.  Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial.. The Journal of infectious diseases. 201(8):1164-8. Abstract